U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07763938) titled 'CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies' on Aug. 09.
Brief Summary: Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies
Study Start Date: Nov. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory B-cell Malignancies
Intervention:
BIOLOGICAL: CD19/CD20 Dual-Target in vivo CAR-T Lentiviral
Prior to infusion of theCD19/CD20 Dual-Target in vivo CAR-T Lentiviral product, subjects may receive bridging ...